ArticleNutrients2015
In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: A Case of Padma Hepaten® Formulation.
Article in Nutrients, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 71 citations in OpenAlex.
- Urolithin as a Metabolite of Ellagitannins and Ellagic Acid from Fruits and Nuts Produced by the Gut Microbiota: Its Role on Non-Communicable Diseases.Current nutrition reports · 2025Review
- Myrobalan Fruit Extracts Modulate Immunobiochemical Pathways In Vitro.Antioxidants (Basel, Switzerland) · 2025Article
- Triphala's characteristics and potential therapeutic uses in modern health.International journal of physiology, pathophysiology and pharmacology · 2025Review
- Study on Quality Characteristic of Chebulae Fructus and Its Adulterants and Degradation Pathway of Hydrolyzable Tannins.Molecules (Basel, Switzerland) · 2024Article
- Urolithin B protects PC12 cells against glutamate-induced toxicity.Molecular biology reports · 2024Article
- Gut microbial metabolites of dietary polyphenols and their potential role in human health and diseases.Journal of physiology and biochemistry · 2023Review
- Urolithin C reveals anti-NAFLD potential via AMPK-ferroptosis axis and modulating gut microbiota.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Insights into the potential benefits of triphala polyphenols toward the promotion of resilience against stress-induced depression and cognitive impairment.Current research in food science · 2023Review
- Polyphenols as Drivers of a Homeostatic Gut Microecology and Immuno-Metabolic Traits ofInternational journal of molecular sciences · 2022Review
- Polyphenols for Livestock Feed: Sustainable Perspectives for Animal Husbandry?Molecules (Basel, Switzerland) · 2022Review
- Review
- Water-Soluble Melanoidin Pigment as a New Antioxidant Component of Fermented Willowherb Leaves (Antioxidants (Basel, Switzerland) · 2021Article
- Neuroprotective Herbs for the Management of Alzheimer's Disease.Biomolecules · 2021Review
- Protective Effect of Triphala against Oxidative Stress-Induced Neurotoxicity.BioMed research international · 2021Article
- Urolithin A Inhibits Epithelial-Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway.OncoTargets and therapy · 2021Article
- Hepatoprotective Effects of Different Extracts FromFrontiers in pharmacology · 2021Article
- Profile of phenolic acids, antioxidant activity and total phenolic compounds during blue corn tortilla processing and its bioaccessibility.Journal of food science and technology · 2020Article
- Potential of the ellagic acid-derived gut microbiota metabolite - Urolithin A in gastrointestinal protection.World journal of gastroenterology · 2020Review
- LC-MS Profile, Gastrointestinal and Gut Microbiota Stability and Antioxidant Activity ofAntioxidants (Basel, Switzerland) · 2020Article
- Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chebulic ellagitannins (ChET) are plant-derived polyphenols containing chebulic acid subunits, possessing a wide spectrum of biological activities that might contribute to health benefits in humans. The herbal formulation Padma Hepaten containing ChETs as the main phenolics, is used as a hepatoprotective remedy. In the present study, an in vitro dynamic model simulating gastrointestinal digestion, including dialysability, was applied to estimate the bioaccessibility of the main phenolics of Padma Hepaten. Results indicated that phenolic release was mainly achieved during the gastric phase (recovery 59.38%-97.04%), with a slight further release during intestinal digestion. Dialysis experiments showed that dialysable phenolics were 64.11% and 22.93%-26.05% of their native concentrations, respectively, for gallic acid/simple gallate esters and ellagitanins/ellagic acid, in contrast to 20.67% and 28.37%-55.35% for the same groups in the non-dialyzed part of the intestinal media. Investigation of human gut microbiota metabolites of Padma Hepaten and pure ChETs (chebulinic, chebulagic acids) established the formation of bioactive urolithins (A, B, C, D, M5). The fact of urolithin formation during microbial transformation from ChETs and ChET-containing plant material was revealed for the first time. Evaluation of the protective effect of ChETs colonic metabolites and urolithins on tert-butyl hydroperoxide (t-BHP)-induced oxidative injury in cultured rat primary hepatocytes demonstrated their significant reversion of the t-BHP-induced cell cytotoxicity, malonic dialdehyde production and lactate dehydrogenase leakage. The most potent compound was urolithin C with close values of hepatoprotection to gallic acid. The data obtained indicate that in the case of Padma Hepaten, we speculate that urolithins have the potential to play a role in the hepatic prevention against oxidative damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.